SuperworthCo-Diagnostics CODX
- Market cap
- $3.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $721.4K
- −28% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −805.4%
Co-Diagnostics trades at 4.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $721.4K over the last twelve months, down 28% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.5M−52% | $3.6M+154% | $467.9K−22% | $2.7M+1243% | $641.1K−74% | $149.3K−96% | $50.3K−89% | $162.9K−94% | $145.4K−77% | $263.9K+77% | $146K+190% | $166.1K+2% | |
| Cost of revenue | $255.8K−67% | $3M+475% | $234.5K−53% | $212.1K−54% | $297.4K+16% | $255.1K−91% | $21.6K−91% | $32.1K−85% | $26.3K−91% | $142.4K−44% | $193.8K+798% | $45.3K+41% |
| Gross profit | $2.2M−49% | $587.3K−34% | $233.3K+134% | $2.4M | $343.7K−84% | −$105.7K | $28.7K−88% | $130.8K−95% | $119.1K−65% | $121.5K | −$47.8K | $120.8K−8% |
| R&D | $5.8M+15% | $6.2M+30% | $5.7M+13% | $5.6M−6% | $4.9M−16% | $4.8M−22% | $4.9M−14% | $4.7M−17% | $4.5M−8% | $5.1M+6% | $5.9M+22% | $4.2M−11% |
| SG&A | $5.1M−8% | $5.9M−10% | $4.5M−5% | $4.2M−23% | $5.3M+6% | $6.6M+12% | $3.4M−24% | $3.2M−23% | $2.4M−55% | $2.4M−64% | $3M−13% | $2M−39% |
| −$8.9M+37% | −$11.8M−55% | −$10.3M+3% | −$7.7M−36% | −$10.2M+15% | −$11.9M+1% | −$8.6M−17% | −$8.1M+5% | −$7M−32% | −$26.5M+123% | −$9.2M+8% | −$6.2M−23% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$8.1M+133% | −$10.8M−57% | −$9.3M+16% | −$7.6M−32% | −$9.7M+20% | −$11M+2% | −$7.5M−19% | −$7.7M+2% | −$7.1M−27% | −$26.2M+138% | −$9.1M+22% | −$6.3M−19% |
| −$2.1M+0% | $3.8M | $22.8K | $20.6K | $22.2K | −$8.2K | $12K−47% | $12.3K−40% | −$1.2M | −$473.7K+5695% | $520−96% | $19.2K+56% | |
| Net income | −$6M+340% | −$14.7M−33% | −$9.3M+62% | −$7.6M−15% | −$9.7M+62% | −$11M−25% | −$7.5M−19% | −$7.7M+2% | −$5.9M−39% | −$25.7M+133% | −$9.1M+21% | −$6.3M−19% |
| −$6.00+400% | −$15.00−32% | −$9.30+55% | −$7.50−19% | −$9.60+60% | −$10.80−28% | −$7.05−24% | −$7.00−7% | −$4.80−50% | −$13.71+27% | −$4.06−42% | −$1.46−79% | |
| 978.7K−6% | 982.2K−1% | 994.8K+1% | 1M+4% | 1M+4% | 1M+5% | 1.1M+7% | 1.1M+10% | 1.3M+24% | 1.9M+83% | 2.3M+111% | 4.3M+291% |
Revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17: 6 months less the 3 months printed beside them.
R&D: Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Operating income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 12 periods, Q1 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY16: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY16 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x30).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Co-Diagnostics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CODXCo-Diagnostics | $3.4M | n/m | 6.0× | 4.7× | −28% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Co-Diagnostics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .